Kyprolis superior to Velcade in second-line MM

Amgen Inc. (NASDAQ:AMGN) said Kyprolis carfilzomib plus dexamethasone met the primary endpoint of superiority over Velcade bortezomib plus dexamethasone in a planned interim analysis of the Phase III ENDEAVOR trial in second-line multiple myeloma. Kyprolis led to median progression-free survival (PFS) of 18.7 months vs. 9.4 months for the Velcade combo, a benefit of 9.3 months (HR=0.53, 95% CI: 0.44, 0.65).

Amgen EVP of R&D Sean Harper said data from ENDEAVOR are consistent with results of the Phase III ASPIRE trial to treat second-line MM. In that study, Kyprolis had a PFS benefit of 8.7 months over Revlimid lenalidomide (26.3 months vs. 17.6 months, p<0.0001). ...